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doi:10.1Objective: Despite the excellent outcomes in the current era after the Fontan procedure, it continues to have an
inherent risk of failure. Cardiac transplantation provides 1 option for treating these patients; however, the indi-
cations for, timing of, and outcomes after, transplantation remain undefined. We examined our own institutional
experience with transplantation for failed Fontan.
Methods: The records of 155 patients transplanted for congenital heart disease at a single institution from June
1984 to September 2007 were reviewed. Of these patients, 43 had undergone a previous Fontan procedure
(25 male, 15 female; median age, 14.5 years; range, 1–47; 23 classic Fontan, 13 lateral tunnel, 4 extracardiac
conduit, and 3 revised to shunt). The predictors of short- and long-term survival were evaluated, and the Fontan
patients were compared with all other patients with congenital heart disease (n ¼ 129, 78 male, 51 female).
Results: The most common indications for transplantation included protein-losing enteropathy (PLE) (39.5%),
chronic heart failure (41.8%), and acute post-Fontan failure (9.3%). The transplants performed in Fontan pa-
tients were more likely to require pulmonary artery reconstruction (85.4% vs 42.9%; P<.0001) and had longer
cardiopulmonary bypass times (278 vs 179 minutes; P<.0001). The 90-day mortality rate was greater in the
Fontan group (35.0% vs 20.0%; P ¼ .055). No correlation was observed between the interval from Fontan
to transplantation and morality; however, renal failure was a strong predictor of early mortality (odds ratio,
10.8; 95% confidence interval, 1.5–75.7).
Conclusions: Transplantation is an acceptable treatment for patients with a failed Fontan. Clinical factors (in-
stead of the indication for transplantation) appear to have the greatest correlation with early mortality. (J Thorac
Cardiovasc Surg 2012;143:1183-92)T
XSupplemental material is available online.
In 1971, Fontan first described placing the systemic and pul-
monary circulations in series as a treatment for tricuspid
atresia.1 Since then, the use of the Fontan procedure has
been expanded to include a variety of congenital heart de-
fects in which 2 functional ventricles cannot be constructed.
Despite the extraordinary advances that the Fontan proce-
dure and its modifications represent in the care of children
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The Journal of Thoracic and Carongoing concern about the long-term future of the circula-
tion driven by a single ventricle.2,3 More recent
examinations of post-Fontan outcomes have confirmed the
long-term challenges facing these patients in the early and
late postoperative period.4
A range of other pathologic processes (often incom-
pletely understood) can result in progressive morbidity
and mortality after the Fontan procedure, including Fontan
circuit failure with normal ventricular function, severe
growth retardation, intractable arrhythmias, PLE, throm-
botic circuit occlusion, pulmonary arteriovenous malforma-
tions, and, rarely, acute post-Fontan failure. Although some
of these pathologic features might be amenable to Fontan
revision, especially where correctable anatomic problems
or focal atrial arrhythmias predominate, cardiac transplan-
tation often provides the only real alternative for these pa-
tients. Accordingly, we chose to examine our own
experience with cardiac transplantation after failed Fontan
to examine the outcomes and identify the predictors of early
and late post-transplant mortality.METHODS
Patient Population
A retrospective review was performed to identify all patients (both adult
and pediatric) undergoing primary cardiac transplantation at the Columbiadiovascular Surgery c Volume 143, Number 5 1183
Abbreviations and Acronyms
CHD ¼ congenital heart disease
CI ¼ confidence interval
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XUniversity Medical Center from January 1, 1984, to January 1, 2007. The
institutional review board for Columbia University Medical Center ap-
proved the study, and the requirement for informed consent was waived.
A total of 172 patients with congenital heart disease (CHD) underwent
transplantation within the study period. Among the patients with CHD,
43 (25.0%) had undergone a previous Fontan operation; these patients
formed the basis for the present analysis.
Surgical Technique
Because of the potential need for extensive recipient reconstruction, the
margins of donor tissue excised were extended, usually to include the aortic
arch and proximal head vessels, branch pulmonary arteries to the hilum,
and superior vena cava and innominate vein. The preferred method of graft
preservation was a single dose of cold Celsior solution (Genzyme Corpora-
tion, Cambridge, Mass) given by pressurized infusion into the aortic root.
Heart transplantation was performed under hypothermic cardiopulmonary
bypass, with deep hypothermic circulatory arrest as needed. Arterial cannu-
lation was preferentially performed in the aorta, with bicaval venous can-
nulation; groin cannulation was used as necessary. In the early part of the
series, the biatrial anastomosis (as described by Lower and Shumway5)
was used in most patients, but in more recent patients, with the demonstra-
tion of its several advantages,6 the bicaval technique has been preferred,
except in cases in which anatomic considerations preclude its use.7
Data Collection
A hospital chart review was conducted for each identified patient and
their donor, and the data were entered into a computerized database. The
donor and recipient demographic and intraoperative and postoperative vari-
ables were acquired. The follow-up period for the patients with failed Fon-
tan circulation ranged from 0.4 to 19.5 years (median, 30.7 months; mean,
52.5). The survival data were cross-referenced with the Social Security
Master Death Index (available at: http://www.ssdi.rootsweb.ancestry.com).
Statistical Analysis
Univariate andmultivariate statistical methodswere used to identify and
estimate the risk factors for all-cause mortality and 30-, 60-, and 90-day
mortality. In addition, the study population was compared (using similar
techniques) with all other patients with CHD and with all non-CHD pa-
tients who underwent transplantation during the same period.
The methods of statistical analysis included the chi-square test for com-
parisons of dichotomous risk factors with negative outcomes, the Mantel-
Haenszel chi-square test for comparisons taking into consideration disease
severity, and the Wilcoxon test for comparisons of continuous variables
with negative outcomes (P< .05). Life-table estimates (Kaplan-Meier)
were calculated using the LIFETEST procedure of SAS, version 9.13,
for Windows (SAS Institute, Cary, NC) with the log-rank test for differ-
ences between strata.
RESULTS
Baseline Demographics and Clinical Condition at
Transplantation
Fewer patients were younger than 5 years (9.3% vs
36.4%, P ¼ .0007) in the Fontan group than in the group
of other patients with CHD, although the mean age was1184 The Journal of Thoracic and Cardiovascular Sursimilar between the 2 groups (15.8 vs 13.7 years, P ¼ .3).
Patient gender and the indicators of clinical condition at
transplantation did not differ significantly between the 2
groups (Table 1). Both groups had a high incidence of pre-
vious sternotomy, and single ventricle diagnoses were more
common among the Fontan patients (Table 1). The Fontan
patients had lower albumin levels in the week before trans-
plantation (3.7 vs 4.0, P ¼ .02). Among the patients with
a previous Fontan operation, the Fontan circuit was a classic
(atriopulmonary connection) Fontan in 23 patients
(53.5%), a lateral tunnel in 13 (30.2%), an extracardiac
connection in 4 (9.3%), and had been taken down in 3
(7.0%; Table 2).
Previous Surgical Interventions
Of all 172 patients undergoing transplantation for CHD,
72 (41.8%) had a single ventricle. Of these 72 patients, 5
(6.9%) had undergone no previous palliation, 10 (13.9%)
had had only a shunt placed, 14 (19.4%) had undergone
a classic or bidirectional Glenn procedure but no Fontan
procedure, and 43 (59.7%) had undergone the Fontan
procedure.
The median age at Fontan completion was 5.4 years
(mean, 7.4; range, 1–25). Nine patients (20.9%) underwent
the Fontan procedure at our institution (Table 3); the re-
mainder were referred for transplant evaluation after a Fon-
tan procedure at other institutions. The mean interval from
the initial Fontan operation to transplantation was 8.6 years
(range, 6 days to 24.5 years).
Hemodynamics
The mean pretransplant transpulmonary gradient was 7.0
mm Hg, with a mean Fontan conduit pressure of 18.4 mm
Hg (range, 13–25 mm Hg). In the setting of extensive aor-
topulmonary collateral flow, the pulmonary vascular resis-
tance could not be calculated reliably.
Transplant Procedure and Operative Technique
The number of days on the waiting list was similar for
both groups (Fontan, 56.9 vs non-Fontan, 63.5 days;
P ¼ .8). Femoral arterial and venous cannulation was re-
quired in 16 Fontan patients (37.2%). Most other patients
had bicaval venous and aortic arterial cannulations. Rarely
used cannulation sites included the subclavian artery or ca-
rotid artery and the axillary vein or an extracardiac conduit.
Fontan patients were more likely to require pulmonary ar-
tery reconstruction (85.4% vs 42.9%, P<.0001), although
the need for reconstruction of the venous return (19.5% vs
17.7%, P¼ .8) or transplantation to a single lung (4.9% vs
8.0%, P ¼ .5) was similar (Table E1). Most commonly, the
recipient pulmonary artery bifurcation or right pulmonary
artery required reconstruction. Repair of venous return
was most commonly required because of the presence of
a left superior vena cava. Donor tissue (either pulmonarygery c May 2012
TABLE 1. Baseline demographics among 43 patients with ‘‘failed
Fontan’’ compared with all other transplants for congenital heart
disease (n ¼ 129)*
Demographic
Fontan
(n ¼ 43)
Other CHD
(n ¼ 129)
P
value
Gender (male) 28 (65.1%) 78 (65.1%) .59
Blood type
A 19 (46.3%) 49 (41.5%) .4
AB 4 (9.6%) 6 (5.1%)
B 2 (4.9%) 12 (10.2%)
O 16 (39.1%) 51 (42.2%)
Diagnosis
Single ventricle 43 (100.0%) 29 (22.6%) <.0001y
Transposition of the great
arteries
8 (18.6%) 28 (22.1%) .6
Tetralogy of Fallot 1 (3.3%) 15 (15.2%) .09
Pulmonary atresia 4 (13.3%) 22 (22.0%) .3
Pulmonary stenosis 12 (38.7%) 19 (19.6%) .03y
Hypoplastic left heart
syndrome
6 (14.6%) 18 (15.4%) .9
Tricuspid atresia 11 (26.8%) 2 (1.6%) <.0001y
Surgical history
Previous sternotomy 43 (100.0%) 96 (74.4%) .0002y
Aortopulmonary shuntz 31 (72.3%) 80 (62.0%) .2
Classic or bidirectional Glenn 19 (44.2%) 22 (17.1%) .0003y
Both Glenn and shunt 16 (37.2%) 18 (14.0%) .0009y
Hemi-Fontan 2 (4.9%) 0 (0.0%) .02y
Clinical condition
Hospitalized 21 (60.0%) 53 (64.6%) .6
Intensive care unit 14 (40.0%) 29 (35.4%) .6
Mechanical ventilation 7 (20.0%) 19 (21.4%) .9
Creatinine>1.5 6 (15.8%) 6 (14.6%) .9
Ventricular assist device 0 (0.0%) 1 (0.9%) .5
Extracorporeal membrane
oxygenation
5 (12.8%) 5 (4.7%) .08
*Percentages indicate percentage of patients with a risk factor among those for whom
data were available for that risk factor. yStatistically significant. zIncluding Blalock-
Taussig shunts and other surgical systemic-to-pulmonary shunts.
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Xarterial or innominate venous tissue) was the most common
material used for reconstruction, although bovine or peri-
cardial patches were also used, as was atrial tissue (Table
E1). One patient with situs inversus required interatrial baf-
fles to direct left-sided venous return to the donor right
atrium. Baffles were also used to redirect totally anomalous
pulmonary venous return into the donor left atrium in an-
other case.
The cardiopulmonary bypass times (mean, 278 vs
179 minutes; P < .0001) and aortic cross-clamp times
(mean, 104 vs 81 minutes; P ¼ .09) were longer in the
Fontan group. The total donor organ ischemic times
were slightly longer in the Fontan group (258 vs 226 min-
utes, P ¼ .04). Twelve patients (27.9%) in the Fontan
group required a period of circulatory arrest (Table E1),
and a trend was seen toward longer circulatory arrest
times compared with the circulatory arrest required inThe Journal of Thoracic and Carthe other patients with CHD (mean, 50.3 vs 26.1 minutes;
P ¼ .09).
Early Post-Transplant Outcomes
Morbidity. Neurologic events occurred in 8 patients in the
Fontan group, including seizures in 1, strokes in 6, and
a subdural hemotoma in 1 patient (Table E2). Two of the pa-
tients with stroke (33.3%) died before hospital discharge. In
both cases, the stroke was likely related to cardiac arrest,
hypotension, and cerebral hypoxia. Of the other 4 patients,
1 had severe congenital cerebrovascular anomalies identi-
fied in the postoperative period. The other 3 appeared to
have hypoxic/ischemic strokes related to postoperative hy-
potension or cardiac arrest.
Five patients (11.6%) in the Fontan group required dialy-
sis in the postoperative period (Table E3). Only 1 of these
patients had preoperative renal dysfunction, most had com-
plicated postoperative courses, including sepsis and multior-
gan system failure. All 5 patients died before discharge. Six
patients (14.0%) required reoperations for bleeding; the in-
hospital mortality within this group was 50%. Drug-treated
infections (including pneumonia, septicemia, and urinary
tract infections) occurred in 21 patients (48.8%). Of these
patients, 7 (33.3%) died within 90 days of transplantation.
Neither postoperative (32.9 vs 28.1 days, P ¼ .52) nor total
(46.4 vs 58.4 days, P ¼ .25) length of stay differed between
the Fontan and non-Fontan CHD groups.
Mortality. Trends were seen toward increased mortality in
the Fontan group at 30 days (25.0% vs 15.6%, P¼ .16) and
60 days (27.5% vs 18.3%, P ¼ .21) but these did not reach
statistical significance. The 90-day mortality rate was
greater among patients in the Fontan group than among
the other patients with CHD (35.0% vs 20.0%, P ¼ .055;
odds ratio [OR], 2.15; 95% confidence interval [CI],
0.97–4.76), although this was primarily the result of the
high mortality early in our experience (before 2000;
40.9% vs 18.9%, P ¼ .046). Patients with ‘‘failed Fontan’’
who had undergone transplanted after 1999 had similar
mortality to those with other forms of CHD (27.8% vs
22.2%, P ¼ .64). In this later group, early mortality oc-
curred entirely among the adult patients (Table 4).
Among the non-Fontan patients, the univariate predictors
of 30-day mortality included female gender (OR, 3.3; 95%
CI, 1.2–9.5), age younger than 1 year (OR, 4.1; 95% CI,
1.4–12.5), hospitalization at transplantation (OR, 4.5;
95% CI, 0.5–38.9), the need for extracorporeal membrane
oxygenation (OR, 15.4; 95% CI, 1.5–158.2), pretransplant
need for mechanical ventilation (OR, 6.8; 95% CI, 1.9–
24.4), history of aortopulmonary shunt without a subsequent
Glenn procedure (OR, 2.7; 95% CI, 0.9–8.4), and a diagno-
sis of tetralogy of Fallot (OR, 3.6; 95% CI, 1.0–12.8).
Similar factors were important among the patients in the
Fontan group (although the sample size limited the power of
the analyses): hospitalization (0.0% vs 28.6%, P¼ .0492),diovascular Surgery c Volume 143, Number 5 1185
TABLE 2. Patients undergoing transplantation after a ‘‘failed Fontan’’ procedure
Pt.
no. Fontan type Gender
Age at
Fontan
Age at
transplantation
(yr)
Transplantation
year Indication Outcome Cause of death
39 Classic M ?? 16 1989 Chronic failure Died, 16 yr Chronic rejection
49 Classic M 3 y 21 1990 PLE Alive
53 Classic M 4 y 15 1990 PLE Died, POD 30 Sepsis and ARDS
69 Classic
(fenestrated)
M 10 y 15 1992 PLE Alive
73 Take-down F 5 y 15 1992 Chronic failure Died, POD 0 Primary failure
81 Classic M 2 y 10 1992 Chronic failure Alive
82 Lateral tunnel M 3 y 3 1992 Acute failure Died, POD 1 Bleeding
83 Classic M 16 y 16 1992 Chronic failure Died, 5 yr Chronic rejection
787 Classic M 10 y 26 1992 Chronic failure Alive
790 Classic M 13 y 23 1992 Chronic failure Died, POD 1 Bleeding
87 Classic F 5 y 18 1993 Pulmonary AVM Alive
791 Classic M 14 y 20 1993 PLE Died, 14 yr Chronic rejection
91 Lateral tunnel
(fenestrated)
M 1 y, 1 mo 1 1994 Acute failure Alive
98 Classic M 1 y, 11 mo 11 1994 PLE Died, POD 2 Bleeding
99 Classic M 7 12 1994 Chronic failure Died, 6 wk Stroke
379 Lateral tunnel F 5 20 1994 Chronic failure Died, POD 0 Bleeding
794 Classic M 10 26 1994 Chronic failure Died, 7 yr Chronic rejection
105 Classic F 3 8 1995 PLE Alive
113 Classic
(fenestrated)
F 1 y, 8 mo 8 1995 PLE Died, 6 yr Chronic rejection
115 Lateral tunnel M 15 y 16 1995 Chronic failure Alive
145 Classic
(fenestrated)
F 6 y 7 1998 Chronic failure Died, POD 0 Bleeding
155 Classic M 2 y 12 1998 Chronic failure Alive
801 Lateral tunnel F 18 y 31 1998 PLE Died, POD 8 Sepsis
171 Classic F 12 y 23 2000 PLE Alive
198 Lateral tunnel M 2 y 7 2002 Chronic failure Alive
203 Taken-down F 2 y 2 2003 Acute failure Alive
204 Classic M 2 y 13 2003 Chronic failure Alive
205 Take-down F 2 y 7 2003 Pulmonary AVM Alive
207 Lateral tunnel M 3 y 9 2003 Plastic bronchitis Alive
234 Lateral tunnel
(fenestrated)
F 9 y 9 2004 Chronic failure Alive
768 Classic M 10 y 31 2004 PLE Alive
248 Lateral tunnel
(fenestrated)
M 15 y 16 2005 PLE Died, 10 wk Sepsis
249 Extracardiac F 9 y 13 2005 PLE Died, 8 wk Sepsis
251 Extracardiac M 5 y 19 2005 Acute failure Died, POD 0 Hyperkalemic arrest
258 Lateral tunnel
(fenestrated)
M 3 y 3 2005 Chronic failure Alive
261 Classic F 4 y 22 2005 PLE Died, 8 wk Sepsis
510 Extracardiac
(fenestrated)
F 2 y 8 2006 PLE Alive
726 Lateral tunnel F 2 y 10 2006 Pulmonary AVM Died, 4 mo Acute rejection
740 Extracardiac
(fenestrated)
M 1 y, 6 mo 15 2006 PLE Alive
772 Classic M 25 y 47 2006 Chronic failure Alive
757 Classic M 14 y 38 2007 PLE Died, POD 1 Bleeding
844 Lateral tunnel M 2 y 13 2008 PLE Alive
866 Lateral tunnel M 2 y 13 2009 Chronic failure Alive
Pt. no., Patient number; M, male; PLE, protein-losing enteropathy; POD, postoperative day; ARDS, acute respiratory distress syndrome; F, female; AVM, arteriovenous
malformation.
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TABLE 3. Details of Fontan procedure among patients who underwent Fontan procedure
Pt.
no. Year Diagnosis Previous procedures Clinical course
82 1992 DILV with L AV valve atresia, L TGA Pulmonary banding Postoperative ventricular failure requiring
ECMO implantation, transplant 9 d later
91 1994 DORV with interrupted aortic arch Pulmonary banding Postoperative ventricular failure requiring
ECMO implantation, transplant 6 d later
115 1995 Single ventricle with single AV canal, PS None Developed AV valve incompetence requiring
mechanical valve replacement within 2 mo,
progressively worsening cardiac function,
transplant within 6 mo
198 1997 Tricuspid atresia, VSD Pulmonary banding Long-term development of dilated
cardiomyopathy, transplanted 5 y later
234 2004 Unbalanced AV canal with aortic atresia,
hypoplastic left heart
Norwood with central shunt,
BDG w/pulmonary arterioplasty
Fontan procedure included AV valve
annuloplasty and patch enlargement of the L
PA, developed worsening AV valve
regurgitation, high PA pressures, thrombus in
conduit, transplanted approximately 6 wk later
248 1992 Dextrocardia, DORV, common atrium, PS,
TGA, TAPVR
Central shunt, repair of TAPVR Uncomplicated, developed PLE, transplanted 13
yr later
768 1983 DILV Pulmonary banding Uncomplicated, developed PLE, transplanted 19
yr later
844 1997 HLHS Norwood stage 1, BDG Uncomplicated, developed PLE, systemic-
pulmonary collaterals causing hemoptysis,
transplanted 11 years later
866 1997 HLHS Norwood stage 1, BDG Fontan procedure complicated by coagulopathy,
massive epistaxis, and eventual hypotensive
cardiac arrest approximately 1 wk
postoperatively, then a prolonged chylothorax;
subsequent course was uncomplicated until
development of chronic heart failure,
transplanted 12 yr later
Pt. No., Patient number; DILV, double inlet left ventricle; L, left; AV, atrioventricular; TGA, transposition of the great arteries; ECMO, extracorporeal membrane oxygenation;
DORV, double outlet right ventricle; PS, pulmonary stenosis; VSD, ventricular septal defect; BDG, bidirectional Glenn; PA, pulmonary atresia; TAPVR, totally anomalous pul-
monary venous return; HLHS, hypoplastic heart syndrome.
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0.8–40.1), and previous shunt without a Glenn procedure
(OR, 4.3; 95% CI, 0.8–22.5). However, gender was not
a significant predictor of poor outcomes (OR, 1.14; 95%
CI, 0.3–5.0). In addition, a creatinine level greater than
1.5 was also associated with greater early mortality (OR,TABLE 4. Mortality by era of transplantation (among Fontan
patients, n ¼ 43)
Mortality Before 1999 After 1999 P value
30-d 8/23 (34.8%) 2/20 (10.0%) .0550
Age<18 y 5/16 (31.3%) 0/14 (0.0%)*
Age18 y 3/7 (42.9%) 2/6 (33.3%)*
60-d 9/23 (39.1%) 2/20 (10.0%) .0290
Age<18 y 6/16 (37.5%) 0/14 (0.0%)*
Age18 y 3/7 (42.9%) 2/6 (33.3%)*
90-d 9/23 (39.1%) 5/20 (25.0%) .3240
Age<18 y 6/16 (37.5%) 2/14 (14.3%)y
Age18 y 3/7 (42.9%) 3/6 (50.0%)y
*Age<18 years vs age 18 years; P¼ .02. yAge<18 years vs age 18 years;
P ¼ .09.
The Journal of Thoracic and Car10.8; 95% CI, 1.5–75.7). Early mortality was lower among
patients transplanted after 1999 (Table 4). A trend was seen
toward a reduction in 30-day mortality among patients
palliated with a Glenn procedure (17.6%) compared withTABLE 5. Mortality at 30, 60, and 90 days among patients with ‘‘failed
Fontan’’ (n ¼ 43)
Variable Patients (n)
Mortality (%)
30 d 60 d 90 d
PLE 15 14.3 14.3 35.7
Acute failur e/postcardiotomy
shock
4 50.0 50.0 50.0
Chronic failure 17 29.4 35.3 35.3
Plastic bronchitis 1 0.0 0.0 0.0
Pulmonary AVMs 3 0.0 0.0 0.0
Classic 22 22.7 27.3 31.8
Extracardiac 4 25.0 25.0 50.0
Lateral tunnel 11 27.27 27.3 36.4
Take-down 3 33.3 33.3 33.3
PLE, Protein-losing enteropathy; AVMs, arteriovenous malformations.
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FIGURE 1. Fifteen-year Kaplan-Meier post-transplant survival estimates illustrated as a function of previous Fontan procedure among patients with a his-
tory of congenital heart disease (CHD) (P ¼ .12).
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shunted, or Fontan; 28.6%; OR, 0.54; 95% CI, 0.17–1.68).
The elapsed time between the Fontan procedure and trans-
plantation did not affect 30-day survival. Neither did the in-
dication for transplantation, although the sample size limited
the statistical analysis, but the patients transplanted for acute
cardiac failure had poor outcomes (Table 5). Among the
patients with PLE, a creatinine level greater than 1.5 was a
predictor of 30-day mortality (100% vs 13.4%, P ¼ .047);
however, the presence of ascites (OR, 0.75; 95% CI, 0.05–
11.6) or albumin less than 3.0 within 1 month of transplanta-
tion (OR, 0.24; 95% CI, 0.02–3.01) were not.FIGURE 2. Fifteen-year Kaplan-Meier estimates of post-transplant survival
‘‘failed Fontan’’ circulation. AVM, Arteriovenous malformation.
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The long-term survival rate among the 43 patients with
failed Fontan circulation was 62.4% at 1 year, 58.7% at 5
years, and 47.5% at 10 years. Although a trend was seen to-
ward worse long-term survival among the Fontan patients,
this mostly resulted from increased mortality within the first
few months after transplantation. After the early postopera-
tive period, the long-term risk of mortality was similar
(Figure 1).
Among all patients with single-ventricle CHD, a trend
was seen toward improved survival among patients trans-
planted after palliation with either a bidirectional or classicstratified by the indication for transplantation among the 40 patients with
gery c May 2012
FIGURE 3. Fifteen-year Kaplan-Meier estimates of post-transplant survival among all patients transplanted with a single ventricle stratified by the type of
previous surgical palliation performed (P ¼ NS).
Davies et al Cardiothoracic TransplantationGlenn procedure compared with those who did not make it
to a Glenn procedure and those who underwent a Fontan
procedure (Figure 3). Overall, the survival of patients
with a single ventricle was lower than that for patients
with 2 functional ventricles before transplantation
(P ¼ .0321; Figure 4). The indication for transplantation
did not predict long-term survival (Figure 2). Survival
was also similar regardless of whether the patients had asci-
tes at of transplantation.
Transplantation resulted in resolution of PLE in most
long-term survivors. Data were not available for 2 patients,
and 5 patients died before discharge. Of the remaining 9 pa-
tients, 1 did not have resolution of PLE, most likelyFIGURE 4. Fifteen-year Kaplan-Meier estimates of post-transplant survival am
presence or absence of congenital heart disease (CHD), and number of functio
The Journal of Thoracic and Carsecondary to complete occlusion of the central veins above
the superior vena cava; 1 required 646 days to normalize his
albumin level, but he also had a diagnosis of cirrhosis and
hepatitis C. The other 7 patients had normal albumin levels
at a median of 44 days (range, 7–114) after transplantation.
Plastic bronchitis resolved, with normal bronchoscopy find-
ings after transplantation; the pulmonary arteriovenous
malformations also resolved, but took longer.
Causes of Death Within Failed Fontan Group
Three phases of mortality were observed. Within the first
week, most patients who died did so of bleeding causes. Of
the 8 deaths within 1 week of transplantation, 6 wereong all patients undergoing transplantation from 1987 to 2004. Stratified by
nal ventricles before transplantation.
diovascular Surgery c Volume 143, Number 5 1189
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Xsecondary to bleeding, 1 was due to cardiovascular collapse
after a prolonged period of cardiopulmonary bypass, and 1
was due to acute postoperative right ventricular failure.
Since 1995, only 1 patient has died of intractable postoper-
ative bleeding (Table 2). From 1 week to 3 months, most of
the 5 deaths resulted from infectious complications (n ¼ 4,
80%); rejection was the primary cause of death for the re-
maining 5 patients.
The predictors of mortality within 7 days of transplanta-
tion included creatinine greater than 1.5 (OR, 14.0; 95%CI,
1.9–102.9) and the need for mechanical ventilation (OR,
5.5; 95% CI, 0.8–37.6).
DISCUSSION
Placement of the pulmonary circulation in series with the
systemic circulation remains an elegant solution to the pa-
tient with CHD without a functional second ventricle. Re-
cent series have demonstrated excellent early and late
results after the Fontan procedure; however, even contem-
porary series have a persistent percentage of patients with
Fontan failure. Technical issues and the timing of the Fon-
tan procedure may play a role in some cases of failure; how-
ever, even the ‘‘perfect’’ Fontan procedure cannot provide
a permanent solution for every patient.1,2
Although not addressed in the present study, many causes
of Fontan failure are amenable to surgical or interventional
correction, including atrial arrhythmia ablation, atrioven-
tricular valve repair or replacement, and conduit revision.3,4
However, the results of surgical or catheter-based treat-
ments of Fontan failure have often been poor—whether
performed for PLE, arrhythmias, or progressive heart
failure.3,8-10 This has led many centers to undertake
cardiac transplantation as a more definitive treatment of
the failed Fontan procedure.11-14 At Columbia, we have
used cardiac transplantation as the preferred treatment for
Fontan failure in the absence of specific correctable
anatomic issues. With the increasing prevalence of adults
with CHD, the number of patients listed for cardiac
transplantation with Fontan failure can also be expected
to increase.15
Unfortunately, few studies have systematically evaluated
patients who have undergone transplantation after a failed
Fontan procedure to assess their outcome compared with
other patients with CHD, leaving clinicians largely in the
dark about the expected outcomes after transplantation. In
the present study, we report our single-institution experi-
ence with transplantation as treatment of the failing Fontan
circulation.
The early mortality after transplantation was high but,
consistent with our experience among all patients with
CHD, recent survival has improved compared with earlier
experience.16 Most notably, since 2000, only a single pa-
tient has died of postoperative bleeding. The early experi-
ence included a significant learning curve with the1190 The Journal of Thoracic and Cardiovascular Surmethods of pulmonary artery reconstruction and recon-
struction of the venous return, including the use of baffles
to correct pulmonary venous return, as appropriate. The re-
duction in postoperative hemorrhagic deaths suggests that
many of these technical hurdles have been overcome.
Despite these improvements, transplantation for the fail-
ing Fontan circulation remains a technically demanding sur-
gery, frequently needing complex pulmonary artery
reconstruction, long bypass times, and periods of deep hy-
pothermic circulatory arrest. Increased experience with
these technical aspects and the resultant decreases in oper-
ative times and technical complications likely played a role
in the decreased incidence of bleeding and early postopera-
tive death. Other possible contributors to the improvement
in early outcomes include the increased use of antifibrino-
lytic agents, more careful patient selection (both transplan-
tation of patients before the onset of end-organ—especially
liver—failure and the refusal to transplant patients already
in liver failure), and more meticulous attention to hemosta-
sis with the recognition of the significant contribution of
hemorrhage to early postoperative death.
Recent data from Kanter et al17 reports mortality among
the Fontan patients that is equivalent to that among non-
Fontan transplantations (including, presumably, patients
with cardiomyopathy). Although superficially at odds
with our results, close inspection shows that the differences
are mostly related to the patients included in the study; in
our most recent era, we had no mortality within 30 days
among the pediatric Fontan patients. Adult patients provide
additional challenges, especially with regard to bleeding in
patients with hepatic congestion and relative hepatic dys-
function. Evaluations of hepatic function are performed in
all patients, although biopsy usually shows findings consis-
tent with congestive heart failure. Most patients with a fail-
ing Fontan will have some degree of liver dysfunction and
coagulopathy, but quantifying this dysfunction is helpful
in planning the implantation procedure.
While mundane, it bears repeating that planning for ster-
nal re-entry is a critical part of the procedure; cross-sec-
tional imaging should be used as necessary to determine
a safe reentry strategy in these patients where injury to
the right atrium may quickly result in massive systemic
air embolus.
The other critical technical aspect of the operation is re-
construction of the pulmonary arterial pathway. Although
most reconstructions in our series were performed using do-
nor tissue, other materials have also been used successfully.
Therefore, waiting for the ‘‘perfect’’ donor from whom ex-
tensive donor tissue can be included as a part of the cardiec-
tomy could needlessly prolong the waiting list time.
Close coordination between the donor and recipient sur-
geons during these procedures is essential, given the combi-
nation of multiple reoperative surgery, long travel times for
retrieval of pediatric organs, and complex anatomicgery c May 2012
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low for the recipient dissection time can result in the donor
organ spending additional time on ice, compromising post-
transplant cardiac function.We have demonstrated mean or-
gan ischemic times of less than 5 hours, only 30 minutes
longer than the patients in the congenital group.
Other investigators have suggested that, among single ven-
tricle patients, transplantation might be best considered as an
alternative to the Fontan procedure in high-risk patients, be-
cause patients transplanted after the Glenn procedure (before
Fontan completion)—even in an earlier and smaller series
from our own institution—had significantly better outcomes
than those who first underwent a Fontan procedure.12,13
However, in the present larger series, we did not find
a dramatic improvement in outcomes when transplantation
occurred before Fontan completion, although a trend was
seen toward improved results among patients with only
a Glenn procedure. This might have been a result of random
variation between the outcomes in groups with small
sample sizes or of differences in patient selection across
series. Alternatively, it might indicate the high morbidity
level among patients with a Glenn procedure referred for
transplantation in an erawith excellent Fontan outcomes.18,19
The mean age at Fontan in these patients was older than 7
years, substantially older than in the typical Fontan series.
This likely reflects the poorer results obtained with late Fon-
tan palliation.19 Although most patients underwent trans-
plant evaluation for single ventricle failure, other
indications included PLE and acute failure after Fontan
conversion. We did not identify any group of patients un-
likely to benefit from transplantation (whether by diagnosis
or by interval between the Fontan procedure and transplan-
tation), although, clearly, patients with acute post-Fontan
failure have high mortality rates even with transplantation.
Unlike other transplant candidates, elevated pulmonary
vascular resistance is rarely a problem in the patients with
failed Fontan circulation. Despite the often elevated
pressures within the Fontan circuit, the transpulmonary gra-
dients remained low in these patients. Accurate measure-
ment of pulmonary vascular resistance in patients with
Fontan circulation is largely precluded by the presence of
significant aortopulmonary collaterals. We have tradition-
ally thought that any increase in pulmonary vascular resis-
tance tolerated by Fontan patients—living without
a pulmonary ventricle—would be too small to pose a risk
to a healthy donor right ventricle. However, we speculate
that accurate measurements of pulmonary vascular resis-
tance might demonstrate some patients in whom transplan-
tation would be less likely to be successful, given that at
least 1 patient died after right ventricular failure during al-
lograft implantation.
Management of the aortopulmonary collaterals in the
pre- and post-transplant period remains challenging. Al-
though coiling might enable more accurate determinationThe Journal of Thoracic and Carof pulmonary vascular resistance, most of these patients
are cyanotic and loss of this pulmonary blood flow would
likely result in worsening hypoxia. In patients with signfi-
cant collaterals, this may necessitate alterations in the car-
diopulmonary bypass stratgey with periods of low flow or
circulatory arrest to minimize pulmonary venous return.
However, in the post-transplant period we have a low
threshhold for returning to the catheterization laboratory
for percutaneous closure of remaining collaterals, espe-
cially in patients showing evidence of high cardiac output.
Consistent with other reports, patients with PLE did not
have greater mortality (even in the presence of ascites),
and resolution of PLE in the post-transplant period was
common.14 Other treatments for PLE have yielded inconsis-
tent results, and the mortality rate at 5 years can exceed
50%.8,20 In the absence of clear and well-defined hemody-
namic problems amenable to correction, transplantation of-
fers the best opportunity for treatment of PLE in patients
with Fontan circulation. Patients with pulmonary arteriove-
nous malformations and plastic bronchitis also had similar
post-transplant outcomes, suggesting that these patients
might benefit significantly from early transplantation, al-
though resolution of arteriovenous malfomations may
take several months.
The optimal timing of transplantation in patients with
a failing Fontan circulation remains problematic. Overall,
the tendency has been to list patients for transplantation ear-
lier in more recent eras (this may be a signficant contributor
to improved outcomes). In that way, we are able to trans-
plant patients with only a failing Fontan, not a failing Fon-
tan with bad ventricular function, poor nutrition, and
marginal renal function.
Although the onset of PLE or ascites did not increase
post-transplant mortality, other clinical parameters did. De-
spite the small sample size, it was clear that once patients
had developed renal dysfunction, survival after transplanta-
tion was markedly decreased. Although preoperative renal
failure is a predictor of poor outcomes in all patients under-
going heart transplantation, patients with 2 ventricles might
be easier to bridge to transplantation while optimizing end-
organ perfusion.21 Single ventricle physiology makes the
use of ventricular assist devices (for both ventricular un-
loading and optimization of perfusion) difficult, and the
poor results suggest that extracorporeal membrane oxygen-
ation is not a preferred alternative as a bridge to transplan-
tation.21 Worsening renal function, where it is thought to be
due to low-cardiac output and possibly reversible, might be
considered an indication for acceleration of listing and ear-
lier transplantation before the development of complete re-
nal failure.
This suggests that patients with failing Fontan circulation
should be evaluated early for transplantation, and transplan-
tation should be performed before Fontan failure, resulting
in significant systemic hypoperfusion. Griffiths et al22 havediovascular Surgery c Volume 143, Number 5 1191
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factor for mortality independent of transplantation, rein-
forcing the need to improve our ability to identify irrevers-
ible Fontan failure in this complicated population and offer
transplantation at an earlier timepoint. Pretransplantation
management should focus on optimizing nutritional and
functional status. We have a low threshhold for admitting
patients with a failing Fontan (especially those with PLE)
for therapy including diuretics, inotropes, and therapeutic
paracentesis. Low-dose inotropes may be helpful, even
among patients with only mild ventricular dysfunction but
with failing Fontan circulation.
Study Limitations
Although this is the largest single-institution series to
date, the small sample size remains a significant limitation
in any analysis of transplantation for the failing Fontan cir-
culation because it limits the ability to perform multivariate
analysis. Even with univariate analysis, to have a 90%
chance of detecting a twofold increase in mortality from
15% to 30%, a sample of 162 patients would have been re-
quired. However, patients with failing Fontan circulation
(especially when they undergo transplantation in adult-
hood), might not be accurately captured in any existing da-
tabase, leaving small single-institution studies such as ours
the only method for examining the outcomes in these pa-
tients. In addition, to maximize the number of patients we
examined, it was necessary to include a long period in the
analysis, and peritransplant management has changed sig-
nificantly from 1984 to 2007 (as evidenced by the reduced
mortality rates after the more recent transplants).
CONCLUSIONS
Despite these limitations, these data support several
conclusions. First, early mortality after transplantation
for the failing Fontan circulation is greater than among
patients with CHD and 2 functional ventricles. The im-
proving results during the past 2 decades reinforce the
need to refer these patients to centers with experience in
transplantation involving complex congenital disease;
however, the perioperative mortality remains high and
consideration of the use of alternate listing strategies for
these patients might enable maximization of the limited
supply of donor allografts. Second, the results in the
most recent decade have improved, and we could not
identify any patients with failed Fontan circulation not
amenable to transplantation in the current era. Third, the
indicators of clinical status at transplantation, including
renal failure, rather than the specific diagnosis or
indication for transplantation, were the strongest predic-
tors of poor survival. Finally, perhaps the most important
lesson is that early referral for transplantation—before the
development of nutritional debilitation, cachexia, and
even subtle end-organ injury—is crucial to optimizing1192 The Journal of Thoracic and Cardiovascular Surpost-transplant outcomes among patients with a failing
Fontan.
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TABLE E1. Operative details for patients undergoing transplantation for failed Fontan (n ¼ 43)
Pt. no. CPB time TCA time Ischemic time Anastomosis Complex reconstruction
39 134 0 109 Biatrial None
49 249 0 228 Biatrial Donor PA used to reconstruct recipient pulmonary artery bifurcation
53 289 0 253 Biatrial Donor PA used to reconstruct recipient pulmonary artery bifurcation
69 377 0 397 Biatrial 10-mm Dacron graft used to replace R PA
73 286 54 281 Biatrial Donor PA used to reconstruct recipient pulmonary artery bifurcation
Donor SVC used to reconstruct recipient SVC
81 147 0 152 Biatrial Donor PA used to reconstruct recipient pulmonary artery bifurcation
82 183 0 192 Biatrial Pericardial patch to reconstruct R PA
83 311 1 339 Biatrial None
787 420 0 360 Bicaval 12-mm PTFE graft used to replace R PA
790 426 61 327 Bicaval 12-mm PTFE used to replace R and L PAs
87 247 65 193 Bicaval Donor PA used to reconstruct recipient pulmonary artery bifurcation
791 369 0 172 Biatrial Interatrial baffle to direct L SVC and L IVC to R side (situs inversus)
91 292 48 331 Biatrial Donor PA used to reconstruct recipient pulmonary artery bifurcation
Recipient coronary sinus L in situ to drain L SVC
98 253 0 270 Biatrial Donor PA used to reconstruct recipient pulmonary artery bifurcation
99 309 0 151 Bicaval Autologous pericardium to reconstruct R PA
379 487 50 292 Bicaval 12-mm PTFE used to replace R and L PAs
794 274 80 220 Biatrial None
105 240 0 220 Biatrial Donor PA used to reconstruct recipient R PA
113 188 0 239 Bicaval Patch used to reconstruct R PA
115 205 0 190 Bicaval None
145 330 0 343 Bicaval Donor PA used to reconstruct recipient pulmonary artery bifurcation
155 318 0 443 Biatrial Donor PA used to reconstruct recipient pulmonary artery bifurcation
801 0 Bicaval Donor PA used to reconstruct recipient pulmonary artery bifurcation
Bovine pericardial baffle used to connect L and R SVCs
171 243 0 330 Bicaval Donor PA used to reconstruct recipient pulmonary artery bifurcation
198 0 202 Bicaval Donor PA used to reconstruct recipient pulmonary artery bifurcation and
R PA
203 173 0 160 Bicaval Pulmonary homograft used to reconstruct R and L PAs
204 210 0 267 Bicaval None
205 198 0 233 Bicaval Donor PA used to reconstruct recipient R and L PAs
207 175 0 220 Bicaval Transplant to single R lung, baffled PA anastomosis
234 191 18 306 Bicaval Donor PA used to reconstruct recipient pulmonary artery bifurcation
L SVC anastomosed to donor innominate vein
Hemiarch replacement performed for transverse aortic arch stenosis
768 234 0 Bicaval Donor PA used to reconstruct recipient pulmonary artery bifurcation
248 234 0 164 Bicaval Donor PA used to replace bifurcation and R PA
Donor PA used to reconstruct anterior SVC
249 351 0 285 Bicaval Donor/recipient atrial tissue to baffle anomalous pulmonary venous
return from R to L atrium
Donor PA anastomosis made to previous Gore-Tex tube graft
replacement of bilateral pulmonary arteries
L SVC anastomosed to donor innominate vein
R SVC of negligible size, oversewn
251 326 39 399 Bicaval Site of previous Glenn shunt on R PA replaced with bovine pericardium
258 321 10 362 Bicaval L SVC thromboembolectomy
L SVC anastomosed to donor innominate vein
Donor PA used to reconstruct R and L PAs
Patch angioplasty of R SVC using donor aorta
261 314 0 Bicaval Recipient R atrial tissue and donor PA used to replace pulmonary artery
bifurcation
510 322 120 205 Bicaval L SVC anastomosed to donor innominate vein
Donor PA used to reconstruct pulmonary artery bifurcation
(Continued)
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TABLE E1. Continued
Pt. no. CPB time TCA time Ischemic time Anastomosis Complex reconstruction
726 244 238 Bicaval L SVC of negligible size, oversewn
Donor PA used to reconstruct R and L PAs
740 376 64 294 Bicaval Bovine pericardial patch angioplasty of R PA
Pulmonary homograft reconstruction of anterior of L and R PA
772 277 0 338 Bicaval Unifocalization of branch pulmonary arteries
Patch angioplasty of R PA using recipient atrium
Donor PA used to reconstruct anterior of pulmonary artery bifurcation
757 480 54 275 Biatrial Donor PA onlay patch angioplasty of pulmonary artery bifurcation
844 171 0 194 Bicaval Patch angioplasty of R PA using bovine pericardium
866 176 0 133 Bicaval Patch angioplasty of R PA using donor L atrial tissue
Pt. no., Patient number; CPB, cardiopulmonary bypass; TCA, total circulatory arrest; PA, pulmonary artery; R, right; SVC, superior vena cava; PTFE, polytetrafluoroethylene;
L, left; IVC, inferior vena cava.
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TABLE E2. Incidence of neurologic events for patients undergoing transplantation for failed Fontan (n ¼ 4)
Variable Pt. no. Year TCA (min) Clinical course Brain imaging Clinical outcome
Stroke
82 1992 None On ECMO before transplantation;
neurologic status not clear
immediately before
transplantation; re-explored for
bleeding; died POD 1 of
intractable bleeding
None Died POD 1
91 1994 49 POD 4 with cardiac arrest,
subsequently with decreased
right-sided movement
MRI, subcortical lesions c/w
hypotensive episode
Mild decrease in RUE strength at
discharge; alive
99 1994 None Extubated POD 2 but subsequent
course complicated by
multiorgan system failure and
cardiac arrest; POD 30 with
symmetric strength, but then
with cardiac arrest and then
bihemispheric stroke
EEG consistent with severe
bihemispheric injury
Died POD 40
113 1995 None No intraoperative issues; multiple
seizures in postoperative period
CT, bihemispheric small infarcts,
L frontal, R occipital/parietal,
old pontine lesions c/w
watershed infarcts
Walking with assistance, speaking
sentences, severe cognitive
deficits; died 6 yr after
transplant
772 2006 None Required re-exploration for
bleeding on POD 1, factor 7
given, systolic blood pressure
in 80s; L upper extremity
weakness noted POD 1
CT, R frontal subcortical infarct,
no hemorrhage
Still with decreased strength and
numbness in LUE/LLE; alive
234 2004 18 POD 16, seizures and later facial
weakness, small acute bleeding
site on imaging
CT/MRI, multiple regions of
arterial stenoses/dilations, tight
vertebral artery stenosis,
impaired cerebral perfusion;
likely old caudate infarct with
post-transplant bleed
Facial weakness resolved before
discharge; no sequelae; alive
Subdural
510 2006 120 POD 3 with right-sided weakness CT/MRI, small subdural
hematoma, no evidence of
stroke
No deficits on neurologic
examination at discharge; alive
Seizure
768 2004 None Intraoperative course with severe
protamine reaction;
postoperative course
complicated by vasodilatory
shock, renal failure,
pneumonia; 2 complex partial
seizures treated with Keppra
CT, no infarct, hemorrhage, mass
effect
No neurologic sequelae; alive
Pt. no., Patient number; TCA, total circulatory arrest; ECMO, extracorporeal membrane oxygenation; POD, postoperative day; R, right; MRI, magnetic resonance imaging;
RUE, right upper extremity; EEG, electroencephalogram; CT, computed tomography; L, left; LUE, left upper extremity; LLE, left lower extremity.
Davies et al Cardiothoracic Transplantation
The Journal of Thoracic and Cardiovascular Surgery c Volume 143, Number 5 1192.e3
T
X
TABLE E3. Clinical course of 5 patients requiring post-transplant dialysis
Pt. no. Age (yr) Year Postoperative clinical course Preoperative clinical status Outcome
99 13 1994 CVVH 3 1 d in setting of cardiopulmonary
arrest and sepsis
Normal renal function Died POD 40
82 3 1992 Immediate postoperative course required
re-exploration for bleeding, profound
hypotension
On ECMO with renal failure, dialysis
initiated before ECMO
Died POD 1
249 13 2005 Postoperative course complicated by sepsis,
including aspergillosis, CVVH initiated on
day of death
Normal renal function Died POD 60
251 20 2005 Patient received hemodialysis
intraoperatively for intractable
hyperkalemia; could not be resuscitated
Normal renal function Died POD 0 in OR
261 22 2005 Complicated postoperative coursewith sepsis
and multiorgan system failure, CVVH
required intermittently until death
Normal renal function Died POD 63
Pt. no., Patient number; CVVH, continuous venovenous hemofiltration; POD, postoperative day; ECMO, extracorporeal membrane oxygenation; OR, operating room.
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